JP2021514661A - サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 - Google Patents

サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 Download PDF

Info

Publication number
JP2021514661A
JP2021514661A JP2020546407A JP2020546407A JP2021514661A JP 2021514661 A JP2021514661 A JP 2021514661A JP 2020546407 A JP2020546407 A JP 2020546407A JP 2020546407 A JP2020546407 A JP 2020546407A JP 2021514661 A JP2021514661 A JP 2021514661A
Authority
JP
Japan
Prior art keywords
seq
cancer
cbd
peptide
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514661A5 (https=
Inventor
ジェフリー エイ． ハッベル
ジェフリー エイ． ハッベル
純 石原
純 石原
亜香 石原
亜香 石原
光一 佐々木
光一 佐々木
メロディー シュワルツ
メロディー シュワルツ
アスラン マンスロフ
アスラン マンスロフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2021514661A publication Critical patent/JP2021514661A/ja
Publication of JP2021514661A5 publication Critical patent/JP2021514661A5/ja
Priority to JP2024035825A priority Critical patent/JP2024069367A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020546407A 2018-03-05 2019-03-05 サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 Pending JP2021514661A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024035825A JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638520P 2018-03-05 2018-03-05
US62/638,520 2018-03-05
US201862727156P 2018-09-05 2018-09-05
US62/727,156 2018-09-05
PCT/US2019/020685 WO2019173289A1 (en) 2018-03-05 2019-03-05 Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024035825A Division JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021514661A true JP2021514661A (ja) 2021-06-17
JP2021514661A5 JP2021514661A5 (https=) 2022-03-14

Family

ID=67847453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546407A Pending JP2021514661A (ja) 2018-03-05 2019-03-05 サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物
JP2024035825A Pending JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024035825A Pending JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物

Country Status (7)

Country Link
US (2) US12365714B2 (https=)
EP (1) EP3762407A4 (https=)
JP (2) JP2021514661A (https=)
CN (1) CN112292391A (https=)
AU (2) AU2019232729B2 (https=)
BR (1) BR112020018196A2 (https=)
WO (1) WO2019173289A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
EP4110803A4 (en) * 2020-02-27 2024-03-27 Icahn School of Medicine at Mount Sinai VEGFR-3 ACTIVATING AGENTS AND ONCOLYTIC VIRUSES AND THEIR USES FOR THE TREATMENT OF CANCER
US20240101630A1 (en) * 2020-12-18 2024-03-28 Cullinan Amber Corp. Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
CN113350522B (zh) * 2021-05-21 2022-08-30 浙江大学杭州国际科创中心 一种铂铜合金/氯离子转运体复合肿瘤治疗制剂及其制备方法、应用
CN116999539A (zh) * 2022-04-28 2023-11-07 天津大学 结直肠癌免疫治疗药物ifnbcol01
WO2025010111A1 (en) * 2023-07-05 2025-01-09 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
WO2025245169A1 (en) * 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315253A1 (en) * 2005-12-26 2014-10-23 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
JP2020501510A (ja) * 2016-09-20 2020-01-23 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
US6211159B1 (en) 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
DE69817393T2 (de) 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
ATE316980T1 (de) 1999-07-21 2006-02-15 Univ Southern California Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
US7192725B2 (en) 2000-05-19 2007-03-20 University Of Toronto Flagellin gene, flaC of Campylobacter
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
US20050037962A1 (en) 2002-01-18 2005-02-17 Ekker Stephen C. Syndecans and angiogenesis
EP3006043B1 (en) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
WO2005082941A1 (en) * 2004-02-27 2005-09-09 The University Of Western Ontario Bone sialoprotein collagen-binding peptides
US8273357B2 (en) 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
AU2006241149A1 (en) 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
JP4538522B2 (ja) 2005-11-25 2010-09-08 コーリー ファーマシューティカル ゲーエムベーハー 免疫刺激性オリゴリボヌクレオチド
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
US20080160024A1 (en) * 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
AT504685B1 (de) 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
US9879062B2 (en) 2012-07-03 2018-01-30 Ecole Polytechnique Federale De Lausanne Protein-binding peptide isolated from placenta growth factor
MX387323B (es) * 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
WO2016054107A1 (en) 2014-09-29 2016-04-07 Counterpoint Biomedica Llc Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
WO2018184003A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
US11574747B2 (en) * 2017-04-20 2023-02-07 The University Of Chicago Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
US20210221864A1 (en) 2018-08-24 2021-07-22 City Of Hope Masked cytokine conjugates
CN113710229B (zh) * 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315253A1 (en) * 2005-12-26 2014-10-23 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
JP2020501510A (ja) * 2016-09-20 2020-01-23 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物

Also Published As

Publication number Publication date
AU2024259762A1 (en) 2024-11-28
CN112292391A (zh) 2021-01-29
US12365714B2 (en) 2025-07-22
US20210094995A1 (en) 2021-04-01
US20260049115A1 (en) 2026-02-19
JP2024069367A (ja) 2024-05-21
AU2019232729A1 (en) 2020-10-08
EP3762407A1 (en) 2021-01-13
EP3762407A4 (en) 2021-11-24
AU2019232729B2 (en) 2024-08-08
WO2019173289A1 (en) 2019-09-12
BR112020018196A2 (pt) 2020-12-29

Similar Documents

Publication Publication Date Title
US20260049115A1 (en) Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines
US20230377764A1 (en) Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies
KR102447396B1 (ko) 세포 표적화된 활성 성분 전달 시스템
EP2170931A1 (en) Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
JP2025089477A (ja) 細胞免疫療法を増強するための方法
CN112955168A (zh) 与另一种药理活性剂组合的长效白介素-15受体激动剂
US20210106652A1 (en) Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
CN119256005A (zh) Il-21多肽和使用方法
JP2025121986A (ja) コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
JP2012520081A (ja) Ｓｐａｒｃ血管新生ドメイン及び使用方法
JP2020501513A (ja) 治療用多標的コンストラクトおよびその使用
US20190125895A1 (en) Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2013140317A2 (en) Peptides
BR122026001844A2 (pt) Polipeptídeo compreendendo um peptídeo de afinidade com ecm ligado a citocina, vetor de ácido nucleico e composição compreendendo o dito polipeptídeo, bem como método para preparar o mesmo e uso do mesmo ou da composição para tratar câncer
JP6222648B2 (ja) 腫瘍ワクチン効果を有する複合体及びその用途
이나경 Immunogenic cell death inducer and oral anticoagulant for potentiating the therapeutic efficacy of immune checkpoint inhibitors
CN117777303A (zh) 一种高亲和力pd1蛋白偶联物及其应用
CN121693512A (zh) 包括用于治疗癌症的工程化il-7多肽和工程化il-12多肽的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230327

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240726